First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET
CA177-1036
Phase 1 other active
Quick answer
First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET for Phase 1: Advanced solid tumors harboring genetic alterations in MET is a Phase 1 program (other) at Turn Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Turn Therapeutics
- Indication
- Phase 1: Advanced solid tumors harboring genetic alterations in MET
- Phase
- Phase 1
- Modality
- other
- Status
- active